Coexistence of the OEM Business and In-House Sales
First written in FY2016. 16 of 41 entries say "Advanced", first in FY2017. Latest entry: 2026-09-28.
No other company in this theme has enough history to compare yet.
- 2026-09-28AdvancedManagement planning
「Planned launch of 2 new ODM products」
ODM事業について、新規ODM製品2機種の上市予定が具体的に示された。 - FY2026AdvancedAnnual report
「Steady overseas sales of ODM products and own-brand products, primarily to major European customers, resulted in net sales of ¥1,901 million for the fiscal year, up 38.0% from the previous fiscal year.」
Under the sales model combining ODM products and own-brand products, overseas sales of the PSS platform increased 38.0% from the previous fiscal year. - FY2026-H1AdvancedAnnual report
「Overseas sales of ODM products, primarily to major European customers, performed steadily, resulting in net sales of ¥991 million for the six months ended September 30, up 46.5% year on year.」
Under a sales structure whose description has shifted from the conventional combination of OEM and own-brand sales to one centered on ODM, overseas sales of ODM products, primarily to major European customers, increased 46.5% year on year. - FY2025ReframedAnnual report
「These products are marketed worldwide, primarily through ODM sales under agreements with global industry leaders, with sales conducted under the customers' brands following contracted design and development from the product-design stage, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States.」
The description of the business model changed from being centered on conventional OEM sales to being centered on ODM, in which development is undertaken from the product-design stage. The structure combining ODM sales with own-brand sales in Japan and overseas has continued. - FY2025-H1AdvancedAnnual report
「Sales in the six-month period of the current consolidated fiscal year were ¥900 million, up 36.7% year on year, driven by higher sales of OEM instruments.」
Within the dual model combining OEM and own-brand sales, OEM sales of clinical diagnostic equipment increased 36.7% year on year. - FY2024AdvancedAnnual report
「The Company and ELITechGroup have agreed to a medium- to long-term supply agreement for OEM products, with a five-year contract period from July 2024 to June 2029, to achieve more stable production and supply of OEM products. Orders totaling at least ¥7 billion are expected to be placed during the contract period.」
Regarding the policy of combining OEM and own-brand sales, the Company reported concrete progress in agreeing with ELITechGroup to a five-year medium- to long-term supply agreement accompanied by expected orders totaling at least ¥7 billion. - FY2024-Q3Overall revenue continued to decline as lower sales of own-brand products and reagents offset steady OEM equipment salesAnnual report
「OEM equipment sales performed steadily, but sales of own-brand fully automated PCR testing systems and related dedicated reagents and consumables declined in both Japan and overseas markets because of the effects of the COVID-19 pandemic moving toward an end, resulting in lower revenue and profit year on year.」
While OEM equipment sales remained steady, domestic and overseas sales of own-brand PCR testing systems and related reagents and consumables declined, and revenue and profit continued to decline across the dual sales model. - FY2024-Q2Overall revenue declined as lower sales of own-brand products and reagents offset steady OEM equipment salesAnnual report
「OEM equipment sales performed steadily, but sales of own-brand fully automated PCR testing systems and related dedicated reagents and consumables declined in both Japan and overseas markets because of the effects of the COVID-19 pandemic moving toward an end, resulting in lower revenue and profit year on year.」
The model combining OEM sales and own-brand sales has continued, but the decline in domestic and overseas sales of own-brand PCR systems and related reagents and consumables offset steady OEM equipment sales, resulting in lower revenue and profit overall. - FY2024-Q1Overall revenue declined as lower sales of own-brand equipment and reagents offset steady OEM equipment salesAnnual report
「OEM equipment sales performed steadily, but sales of own-brand equipment, reagents and consumables declined as the COVID-19 pandemic moved toward an end, resulting in lower revenue and profit year on year.」
While OEM equipment sales were steady, lower sales of own-brand equipment, reagents and consumables resulted in lower revenue and profit overall under the combined OEM and own-brand sales model. - FY2023Overall revenue declined because of lower overseas sales and other factorsAnnual report
「Overseas sales declined as the COVID-19 pandemic trended toward an end. Although sales of own-brand fully automated PCR testing systems and related dedicated reagents and consumables were in line with the initial plan, domestic orders also declined after COVID-19 was reclassified as a Class 5 disease under Japan's Infectious Diseases Control Law in May 2023. In addition, revenue was affected by the reduction in the reimbursed price for PCR reagents used for COVID-19 testing in Japan.」
The model combining OEM sales and own-brand sales continued, but lower overseas sales, shrinking domestic demand for PCR testing and the reduction in the reimbursed price for PCR reagents resulted in overall revenue declining 29.0% from the previous fiscal year. - FY2023-Q3Overall revenue continued to decline because of lower overseas sales and a revision to reimbursement points for domestic PCR reagentsAnnual report
「These products are marketed worldwide through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. For the nine months ended December 31, net sales were ¥4,207 million, down 23.0% year on year, and gross profit was ¥1,294 million, down 30.9%. Sales of own-brand fully automated PCR testing systems and related dedicated reagents and consumables performed steadily. However, overseas sales declined, mainly because of the effects of the COVID-19 pandemic showing signs of ending, and the revision of reimbursement points for PCR reagents used for COVID-19 testing in Japan resulted in lower revenue and profit year on year.」
The dual model combining OEM sales and own-brand sales through subsidiaries in Japan, Europe and the United States continued. While own-brand products and other items performed steadily, lower overseas sales and the revision of reimbursement points for domestic PCR reagents resulted in net sales declining 23.0% year on year and gross profit declining 30.9%. - FY2023-Q2Overall revenue continued to decline because of lower overseas sales and a revision to reimbursement points for domestic PCR reagentsAnnual report
「Sales of own-brand fully automated PCR testing systems and related dedicated reagents and consumables performed well. However, overseas sales declined, mainly because of the effects of the COVID-19 pandemic showing signs of ending, and the revision of reimbursement points for PCR reagents used for COVID-19 testing in Japan resulted in lower revenue and profit year on year.」
The model centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States has continued, but strong sales of own-brand products and other items were offset by lower overseas sales and the revision of reimbursement points for domestic PCR reagents, resulting in lower revenue and profit overall. - FY2023-Q1Overall revenue declined because of lower overseas sales and a revision to reimbursement points for domestic PCR reagentsAnnual report
「Sales of own-brand fully automated PCR testing systems and related dedicated reagents and consumables performed well. However, overseas sales declined, mainly because of the effects of the COVID-19 pandemic showing signs of ending, and the revision of reimbursement points for PCR reagents used for COVID-19 testing in Japan resulted in lower revenue and profit year on year.」
The model combining OEM sales and own-brand sales through subsidiaries in Japan, Europe and the United States continued, but lower overseas sales and the revision of reimbursement points for domestic PCR reagents resulted in lower revenue and profit overall. - FY2022Overall revenue declined because of lower equipment salesAnnual report
「For the fiscal year, net sales were ¥7,434 million, down 20.1% from the previous fiscal year. Although revenue and profit declined year on year, sales of reagents and consumables for fully automated PCR testing systems and automated DNA extraction systems sold under the domestic own brand and supplied as OEM products to ELITechGroup, as well as maintenance-related sales, performed steadily.」
The model combining OEM sales and own-brand sales through subsidiaries in Japan, Europe and the United States continued. While overall revenue declined 20.1% from the previous fiscal year, primarily because of lower equipment sales, reagents and consumables and maintenance-related sales were reported to have performed steadily. - FY2022-Q3Overall revenue continued to decline because of lower equipment salesAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. For the nine months ended December 31, net sales were ¥5,461 million, down 20.4% year on year, and gross profit was ¥1,874 million, down 17.2%. Although revenue and profit declined year on year, sales of reagents and consumables for fully automated PCR testing systems and automated DNA extraction systems sold under the domestic own brand and supplied as OEM products to ELITechGroup, as well as maintenance-related sales, performed steadily.」
The dual model centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States continued. While overall revenue declined 20.4% year on year because of lower equipment sales, reagents and consumables associated with the domestic own brand and OEM products supplied to ELITechGroup, as well as maintenance-related sales, were reported to have performed steadily. - FY2022-Q2Overall revenue declined because of lower equipment salesAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. For the six months ended September 30, net sales were ¥3,591 million, down 20.6% year on year, and gross profit was ¥1,283 million, down 13.5%. Although revenue and profit declined year on year, sales of reagents and consumables for fully automated PCR testing systems and automated DNA extraction systems sold under the domestic own brand and supplied as OEM products to ELITechGroup, as well as maintenance-related sales, performed steadily.」
The model centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States continued. While overall revenue declined 20.6% year on year because of lower equipment sales, reagents and consumables associated with the domestic own brand and OEM products supplied to ELITechGroup, as well as maintenance-related sales, were reported to have performed steadily. - FY2022-Q1Overall revenue declined despite strong sales of reagents and other products, due to lower equipment salesAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. For the three months ended June 30, net sales were ¥1,871 million, down 9.9% year on year, and gross profit was ¥673 million, down 6.3%. Despite the decline in revenue, sales of reagents and consumables for fully automated PCR testing systems and automated DNA extraction systems sold under the domestic own brand and supplied as OEM products to ELITechGroup performed well.」
The model centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States continued. Overall revenue declined because of lower equipment sales, although reagents and consumables associated with the domestic own brand and OEM products supplied to ELITechGroup performed well. - FY2021-Q3AdvancedAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. For the nine months ended December 31, net sales were ¥6,863 million, up 103.1% year on year, and gross profit was ¥2,264 million, up 120.8%. In particular, sales of own-brand products launched in Japan, fully automated PCR testing systems supplied as OEM products to ELITechGroup, automated DNA extraction systems and related reagents and consumables performed well in response to global demand for rapid definitive COVID-19 testing. Overall, revenue and profit increased year on year.」
The dual sales model, centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States, has continued. Against a backdrop of demand for COVID-19 testing, own-brand products, OEM products supplied to ELITechGroup, automated DNA extraction systems and related reagents and consumables performed well. Net sales increased 103.1% year on year and gross profit increased 120.8%. - FY2021-Q2AdvancedAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. For the six months ended September 30, net sales were ¥4,524 million, up 122.7% year on year, and gross profit was ¥1,484 million, up 154.7%. In particular, sales of own-brand products launched in Japan, fully automated PCR testing systems supplied as OEM products to ELITechGroup, automated DNA extraction systems and related reagents and consumables performed well in response to global demand for rapid definitive COVID-19 testing.」
The dual sales model, centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States, has continued. Strong sales of own-brand products launched in Japan, OEM products supplied to ELITechGroup, automated DNA extraction systems and related reagents and consumables resulted in revenue growth of 122.7% year on year. - FY2021-Q1AdvancedAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. For the three months ended June 30, net sales were ¥2,077 million, up 124.5% year on year, and gross profit was ¥719 million, up 152.7%. In particular, sales of own-brand products launched in Japan, fully automated PCR testing systems supplied as OEM products to ELITechGroup, automated DNA extraction systems, and related reagents and consumables performed well in response to global demand for rapid definitive COVID-19 testing. Overall, revenue and profit increased year on year.」
The dual sales model, centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States, has continued. Strong sales of own-brand products launched in Japan, OEM products supplied to ELITechGroup, automated DNA extraction systems and related reagents and consumables resulted in overall revenue growth of 124.5% year on year. - FY2020RestatedAnnual report
「In any event, we believe that, by making detailed adjustments to product specifications and sales regions, it will be necessary for the OEM supply business and own-brand sales business to coexist for the time being.」
The dual sales strategy of using OEM supply arrangements with major companies while also pursuing own-brand sales has continued. - FY2020-Q3AdvancedAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. For the nine months ended December 31, net sales were ¥3,379 million, up 9.5% year on year. In particular, sales of the fully automated PCR testing systems supplied as OEM products to ELITechGroup, automated DNA extraction systems and related consumables, including extraction reagents and plastic consumables, performed well in response to global demand for rapid definitive COVID-19 testing. Overall, revenue increased year on year.」
The model of centered OEM sales supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States has continued. Against a backdrop of demand for COVID-19 testing, PCR testing systems, automated DNA extraction systems and related consumables performed well, resulting in overall revenue growth of 9.5% year on year. - FY2020-Q2Overall profit declined because equipment sales and contract manufacturing revenue were not recordedAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. Sales of the fully automated genetic diagnostic system supplied as an OEM product to ELITechGroup performed steadily, but equipment sales and contract manufacturing revenue expected from the beginning of the period could not be recorded, resulting in lower profit year on year overall.」
The dual model combining OEM sales and own-brand sales through subsidiaries in Japan, Europe and the United States continued. While OEM products supplied to ELITechGroup performed steadily, the equipment sales and contract manufacturing revenue expected at the beginning of the period were not recorded, resulting in lower profit overall. - FY2020-Q1Despite strong sales of key products, revenue and profit declined overallAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States.」
The dual sales model, centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States, has continued. Sales of OEM products supplied to ELITechGroup and automated DNA extraction systems performed well, but revenue and profit declined year on year overall. - FY2019AdvancedAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. Sales of the fully automated genetic diagnostic system supplied as an OEM product to ELITechGroup and sales of automated DNA extraction systems performed well. Overall, revenue and profit increased from the previous fiscal year.」
The dual sales model, centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States, continued. Strong sales of products supplied to ELITechGroup and automated DNA extraction systems resulted in higher revenue and profit overall. - FY2019-Q3AdvancedAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. For the nine months ended December 31, net sales were ¥3,085 million, up 19.5% year on year, and gross profit was ¥1,052 million, up 12.9%. Sales of the fully automated genetic diagnostic system supplied as an OEM product to ELITechGroup and sales of automated DNA extraction systems performed well. Overall, revenue and profit increased year on year.」
The dual sales model, centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States, has continued. Strong sales of OEM products supplied to ELITechGroup and automated DNA extraction systems resulted in revenue growth of 19.5% year on year overall. - FY2019-Q2AdvancedAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. Sales of the fully automated genetic diagnostic system supplied as an OEM product to ELITechGroup and sales of automated DNA extraction systems performed well. Overall, revenue and profit increased year on year.」
The dual sales model, centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States, has continued. Strong sales of OEM products supplied to ELITechGroup and automated DNA extraction systems resulted in higher revenue and profit overall. - FY2019-Q1Higher revenue and profit driven by strong OEM and own-brand salesAnnual report
「These products are marketed worldwide, primarily through OEM sales under agreements with major companies in the biotechnology-related industry that have global distribution networks, as well as through own-brand sales via subsidiaries in Japan, Europe and the United States. Sales of the fully automated genetic diagnostic system supplied as an OEM product to ELITechGroup and sales of automated DNA extraction systems performed well. Overall, revenue and profit increased year on year.」
The dual sales model, centered on OEM sales and supplemented by own-brand sales through subsidiaries in Japan, Europe and the United States, has continued. Strong sales of OEM products supplied to ELITechGroup and automated DNA extraction systems resulted in higher revenue and profit overall. - FY2018Existing OEM sales weak, own-brand sales strongAnnual report
「Sales of the fully automated genetic testing system supplied as an OEM product to ELITechGroup and own-brand sales performed well, but weak sales to some existing OEM customers resulted in lower revenue year on year overall.」
The dual sales model combining OEM and own-brand sales has continued, but weak sales to existing OEM customers offset strong sales to ELITechGroup and own-brand sales, resulting in lower revenue overall. - FY2018-Q3Existing OEM sales weak, own-brand sales strongAnnual report
「For the nine months ended December 31, net sales were ¥2,582 million, down 8.9% year on year, and gross profit was ¥931 million, down 4.6%. Sales of the fully automated genetic diagnostic system supplied as an OEM product to ELITechGroup and own-brand sales performed well, but sales to existing OEM customers were weak, resulting in lower revenue and profit year on year overall.」
The dual sales model combining OEM and own-brand sales has continued, but weak sales to existing OEM customers offset strong sales to ELITechGroup and own-brand sales, resulting in lower revenue and profit overall. - FY2018-Q2Existing OEM sales weak, own-brand sales strongAnnual report
「Sales of the fully automated genetic diagnostic system supplied as an OEM product to ELITechGroup and own-brand sales performed well, but sales to existing OEM customers were weak, resulting in lower revenue and profit year on year overall.」
The dual sales model combining OEM and own-brand sales has continued. While sales to ELITechGroup and own-brand sales were strong, weak sales to existing OEM customers resulted in lower revenue and profit overall. - FY2018-Q1RestatedAnnual report
「To resolve this situation and achieve profitability at an early stage, the Group has established the following policies for its three-year medium-term business plan: (1) deepen existing OEM relationships and secure new OEM contracts, (2) expand the lineup of proprietary products and strengthen sales, and (3) improve profit margins by reducing product costs, particularly in the reagent business. Through these measures, the Group aims to expand revenue and secure profits.」
The policy of pursuing both deeper OEM relationships and new contracts and sales of proprietary products was reaffirmed as a measure under the three-year medium-term business plan. - FY2017AdvancedAnnual report
「In OEM sales, revenue from the fully automated gene-testing instrument “geneLEAD Ⅻ Plus,” launched in September 2015, doubled year on year as sales progressed steadily. However, revenue declined year on year, largely because product shipments were temporarily suspended at some OEM customers. Direct sales, an area the Company has focused on in recent years, expanded to approximately 1.5 times the previous year's level, but did not offset the decline in OEM sales, resulting in an overall year-on-year decline in revenue.」
The disclosure cited concrete progress in direct sales, which increased to approximately 1.5 times the previous year's level while OEM sales remained the core business. - FY2017-Q3RestatedAnnual report
「The Company operates worldwide, focusing on OEM sales under contracts with major companies in the biotechnology-related industry that have global distribution networks, including sales under the partners' brands, while also conducting direct sales through its subsidiaries in Europe and the United States.」
The sales model of focusing on OEM sales to major companies while also conducting direct sales through subsidiaries in Europe and the United States continues. - FY2017-Q2RestatedAnnual report
「The Company operates worldwide, focusing on OEM sales under contracts with major companies in the biotechnology-related industry that have global distribution networks, including sales under the partners' brands, while also conducting direct sales through its subsidiaries in Europe and the United States.」
The sales policy of focusing on OEM sales while also conducting direct sales through subsidiaries in Europe and the United States was reiterated. - FY2017-Q1RestatedAnnual report
「The Company operates worldwide, focusing on OEM sales under contracts with major companies in the biotechnology-related industry that have global distribution networks, including sales under the partners' brands, while also conducting direct sales through its subsidiaries in Europe and the United States.」
The two-pronged sales policy of focusing on OEM sales while also conducting direct sales through subsidiaries in Europe and the United States continued to be cited. - FY2016First statedAnnual report
「For the time being, the Company believes it needs to maintain both the OEM business and direct sales by making detailed adjustments to product specifications, sales regions and other factors. Through these measures, it plans to develop over the medium to long term into a comprehensive infrastructure provider for the biotechnology-related industry.」
A two-pronged sales policy: use OEM arrangements with major companies while expanding direct sales to reduce dependence on OEM customers.